Case Study: Curious Case of Remicade bio-pharma patent battle with Inflectra
Posted on22 Aug 2016
Tagsbiopharma patent battle, biopharmaceuticals, Celltrion, Hospira, Inflectra, Johnson & Johnson, pfizer, Remicade, Remicade biosimilar
Comments0
Biopharmaceutical: Infliximab Class: monoclonal antibody Brand Name: Remicade Marketed By: Johnson & Johnson ——————————– Biosimilar of Infliximab is Inflectra. ——————————– Infliximab (trade... Read More
Hospira launches generic bivalirudin for injection in US market
Posted on20 Jul 2015
Comments0
The US Food and Drug Administration (FDA) has granted marketing approval for Hospira, Inc.’s bivalirudin for injection, a generic version of The... Read More
Pfenex And Hospira Collaboration To Develop And Commercialize LUCENTIS® Biosimilar
Pfenex Inc, a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., (NYSE: HSP), the world’s leading provider... Read More
Pfizer to acquire Hospira
Posted on11 Feb 2015
Comments0
The pharmaceutical Pfizer giant is purchasing the injectable drugmaker Hospira for a reported $15 billion. This represents a new area for Pfizer.... Read More
Hospira Receives U.S. FDA Approval of Proprietary Analgesic Dyloject Injection
“In today’s healthcare environment, pain management and patient satisfaction are important to hospitals. As a result, various medical organizations are now recommending... Read More